SAN DIEGO, May 14, 2026 /PRNewswire/ — Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
